- Home
- AG vs PCVX Comparison
AG vs PCVX Comparison
Compare AG & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AG | PCVX |
|---|---|---|
| Founded | 1979 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AG | PCVX |
|---|---|---|
| Price | $15.20 | $49.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $14.25 | ★ $101.67 |
| AVG Volume (30 Days) | ★ 15.7M | 1.4M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $965,571,000.00 | N/A |
| Revenue This Year | $107.28 | N/A |
| Revenue Next Year | $18.07 | N/A |
| P/E Ratio | $96.38 | ★ N/A |
| Revenue Growth | ★ 83.84 | N/A |
| 52 Week Low | $5.09 | $27.66 |
| 52 Week High | $15.69 | $94.76 |
Technical Indicators
Market Signals| Indicator | AG | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 69.64 | 65.33 |
| Support Level | $10.72 | $47.02 |
| Resistance Level | $12.40 | $50.27 |
| Average True Range (ATR) | 0.81 | 2.03 |
| MACD | 0.30 | 0.15 |
| Stochastic Oscillator | 98.43 | 93.32 |
Price Performance
Historical ComparisonAbout AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.